BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

498 related articles for article (PubMed ID: 31515284)

  • 21. Doxorubicin as a fluorescent reporter identifies novel MRP1 (ABCC1) inhibitors missed by calcein-based high content screening of anticancer agents.
    Sampson A; Peterson BG; Tan KW; Iram SH
    Biomed Pharmacother; 2019 Oct; 118():109289. PubMed ID: 31401398
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coexpression of ABCB1 and ABCG2 in a Cell Line Model Reveals Both Independent and Additive Transporter Function.
    Robinson AN; Tebase BG; Francone SC; Huff LM; Kozlowski H; Cossari D; Lee JM; Esposito D; Robey RW; Gottesman MM
    Drug Metab Dispos; 2019 Jul; 47(7):715-723. PubMed ID: 31048454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Overexpression of human ATP-binding cassette transporter ABCG2 contributes to reducing the cytotoxicity of GSK1070916 in cancer cells.
    Wu ZX; Mai Q; Yang Y; Wang JQ; Ma H; Zeng L; Chen ZS; Pan Y
    Biomed Pharmacother; 2021 Apr; 136():111223. PubMed ID: 33450491
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
    Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo.
    Lin F; Hoogendijk L; Buil L; Beijnen JH; van Tellingen O
    Eur J Cancer; 2013 May; 49(8):2059-64. PubMed ID: 23422148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
    Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS
    Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.
    Lagas JS; van Waterschoot RA; van Tilburg VA; Hillebrand MJ; Lankheet N; Rosing H; Beijnen JH; Schinkel AH
    Clin Cancer Res; 2009 Apr; 15(7):2344-51. PubMed ID: 19276246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Astragali radix and its main bioactive compounds activate the Nrf2-mediated signaling pathway to induce P-glycoprotein and breast cancer resistance protein.
    Lou Y; Guo Z; Zhu Y; Zhang G; Wang Y; Qi X; Lu L; Liu Z; Wu J
    J Ethnopharmacol; 2019 Jan; 228():82-91. PubMed ID: 30243825
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ribociclib shows potential for pharmacokinetic drug-drug interactions being a substrate of ABCB1 and potent inhibitor of ABCB1, ABCG2 and CYP450 isoforms in vitro.
    Sorf A; Hofman J; Kučera R; Staud F; Ceckova M
    Biochem Pharmacol; 2018 Aug; 154():10-17. PubMed ID: 29673999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. P-glycoprotein--implications of metabolism of neoplastic cells and cancer therapy.
    Breier A; Barancík M; Sulová Z; Uhrík B
    Curr Cancer Drug Targets; 2005 Sep; 5(6):457-68. PubMed ID: 16178819
    [TBL] [Abstract][Full Text] [Related]  

  • 32. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.
    Wang J; Gan C; Retmana IA; Sparidans RW; Li W; Lebre MC; Beijnen JH; Schinkel AH
    Int J Pharm; 2019 Feb; 556():172-180. PubMed ID: 30553002
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overlapping substrate and inhibitor specificity of human and murine ABCG2.
    Bakhsheshian J; Hall MD; Robey RW; Herrmann MA; Chen JQ; Bates SE; Gottesman MM
    Drug Metab Dispos; 2013 Oct; 41(10):1805-12. PubMed ID: 23868912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters.
    Fan YF; Zhang W; Zeng L; Lei ZN; Cai CY; Gupta P; Yang DH; Cui Q; Qin ZD; Chen ZS; Trombetta LD
    Cancer Lett; 2018 May; 421():186-198. PubMed ID: 29331420
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Using the lentiviral vector system to stably express chicken P-gp and BCRP in MDCK cells for screening the substrates and studying the interplay of both transporters.
    Zhang Y; Huang J; Liu Y; Guo T; Wang L
    Arch Toxicol; 2018 Jun; 92(6):2027-2042. PubMed ID: 29725709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis and Characterization of Bodipy-FL-Cyclosporine A as a Substrate for Multidrug Resistance-Linked P-Glycoprotein (ABCB1).
    Sajid A; Raju N; Lusvarghi S; Vahedi S; Swenson RE; Ambudkar SV
    Drug Metab Dispos; 2019 Oct; 47(10):1013-1023. PubMed ID: 31371421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel Heat Shock Protein 90 Inhibitors Suppress P-Glycoprotein Activity and Overcome Multidrug Resistance in Cancer Cells.
    Dinić J; Podolski-Renić A; Jovanović M; Musso L; Tsakovska I; Pajeva I; Dallavalle S; Pešić M
    Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31527404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Species difference in brain penetration of P-gp and BCRP substrates among monkey, dog and mouse.
    Kido Y; Nanchi I; Fusamae Y; Matsuzaki T; Akazawa T; Sawada H; Iwasaki M; Nishida K; Tsuchiya E; Okuda T
    Drug Metab Pharmacokinet; 2022 Feb; 42():100426. PubMed ID: 34974334
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1).
    Kort A; Durmus S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Pharm Res; 2015 Jul; 32(7):2205-16. PubMed ID: 25563977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. LysoTracker and MitoTracker Red are transport substrates of P-glycoprotein: implications for anticancer drug design evading multidrug resistance.
    Zhitomirsky B; Farber H; Assaraf YG
    J Cell Mol Med; 2018 Apr; 22(4):2131-2141. PubMed ID: 29377455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.